Name of Policy:	Room Assignments for Patients Undergoing Administration of Intravenous Chemotherapeutic Agents	THE UNIVERSITY OF TOLEDO MEDICAL CENTER	
Policy Number:	3364-100-01-14		
Department:	Hospital Administration Medical Staff		
Approving Officer:	Chief Executive Officer - UTMC Chief of Staff		
Responsible Agent:	Chief Nursing Officer		
Scope:	The University of Toledo Medical Center and its Medical Staff	Effective Date: 06/01/2021	
		Initial Effective Date: 2/10/1999	
New policy proposal Minor/technical revision of existing policy Major revision of existing policy X Reaffirmation of existing policy			

(A) Policy Statement

Patients undergoing the administration of intravenous chemotherapeutic and/or biotherapy agents shall be admitted to the nursing unit 4CD. This location may be changed upon the medical decision of the attending physician, if the patient requires the service intensity of an Intermediate Care or Intensive Care Unit.

(B) Purpose of Policy

To provide the safest environment possible for patients, health care workers and visitors.

(C) Procedure

- 1. If administration of intravenous chemotherapy is planned during a patient's hospitalization, the patient must be admitted to a room on 4CD per admission orders of a licensed physician unless the patient requires placement in an Intermediate Care or Intensive Care Unit.
- 2. The Admitting Office shall be notified of need for a 4CD bed preferably thirty-six hours in advance of the anticipated admission.
- 3. If the administration of intravenous chemotherapy is decided upon after admission and the patient is not already on 4CD, the attending physician shall request a room transfer to 4CD, unless the patient requires placement in an Intermediate Care or Intensive Care Unit based on admission criteria for these areas.
- 4. If the patient is in an Intensive Care unit or Intermediate Care Unit and requires the administration of intravenous chemotherapy, the Nursing Office should be notified so that an appropriate chemotherapy competent nurse can be assigned to provide this care.
- 5. Nursing staff on 4CD receive specific training and education on the administration of chemotherapy and biologic response modifiers. They maintain competency through regular administration of the agents, peer review, and continuing education.

/s/ 06/11/2021 5/28/2008 Richard Swaine Date 5/1/2011 Chief Executive Officer - UTMC 5/1/2014 5/1/2014 /s/ 06/10/2021 05/01/2021 Andrew Casabianca, MD, DMD Date 05/01/2021 /s/ 06/10/2021 05/01/2021 Andrew Casabianca, MD, DMD Date 05/01/2021 /section Completed By: Manager, Outcome Management 06/10/2021 Chief of Staff Next Review Date: 5/1/2024 5/1/2024	Approved by:		Review/Revision Date: 2/20/02 3/9/05
Chief Executive Officer - UTMC 5/1/2014 /s/ 06/10/2021 Andrew Casabianca, MD, DMD Date Chief of Staff 06/10/2021 Revision Completed By: Manager, Outcome Management Chief Nursing Officer S/1/2014 Chief of Staff Next Review Date: 5/1/2024	/s/	06/11/2021	5/28/2008
/s/ 06/10/2021 /ndrew Casabianca, MD, DMD Date Chief of Staff Date Revision Completed By: Manager, Outcome Management Chief Nursing Officer S/1/2021 Chief of Staff Next Review Date: 5/1/2024	Richard Swaine	Date	5/1/2011
/s/ 06/10/2021 Andrew Casabianca, MD, DMD Date Chief of Staff Revision Completed By: Manager, Outcome Management Chief Nursing Officer Chief of Staff Next Review Date: 5/1/2024	Chief Executive Officer - UTMC		5/1/2014
/s/ 06/10/2021 Andrew Casabianca, MD, DMD Date Chief of Staff Date Revision Completed By:			5/1/2017
Andrew Casabianca, MD, DMD Date Chief of Staff Date Revision Completed By: Manager, Outcome Management Chief Nursing Officer Chief of Staff Chief of Staff Next Review Date: 5/1/2024			05/01/2021
Chief of Staff Revision Completed By: Manager, Outcome Management Chief Nursing Officer Chief of Staff Next Review Date: 5/1/2024	/s/	06/10/2021	
Revision Completed By: Manager, Outcome Management Chief Nursing Officer Chief of Staff Next Review Date: 5/1/2024	Andrew Casabianca, MD, DMD	Date	-
Manager, Outcome Management Chief Nursing Officer Chief of Staff Next Review Date: 5/1/2024	Chief of Staff		
Chief Nursing OfficerChief of StaffNext Review Date:5/1/2024	Revision Completed By:		
Chief of Staff Next Review Date: 5/1/2024	Manager, Outcome Management		
		N (D) D (5/1/2024	
	nemotherapeutic Agents		